A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

1,029

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

March 7, 2023

Study Completion Date

August 15, 2023

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSVPreF3 OA investigational vaccine

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

BIOLOGICAL

FLU HD vaccine

FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).

Trial Locations (46)

15243

GSK Investigational Site, Pittsburgh

21045

GSK Investigational Site, Columbia

27804

GSK Investigational Site, Rocky Mount

28401

GSK Investigational Site, Wilmington

28601

GSK Investigational Site, Hickory

29303

GSK Investigational Site, Spartanburg

29405

GSK Investigational Site, North Charleston

30328

GSK Investigational Site, Sandy Springs

31406

GSK Investigational Site, Savannah

32801

GSK Investigational Site, Orlando

33012

GSK Investigational Site, Hialeah

33016

GSK Investigational Site, Miami

33134

GSK Investigational Site, Coral Gables

33184

GSK Investigational Site, Miami

33409

GSK Investigational Site, West Palm Beach

33912

GSK Investigational Site, Fort Myers

34142

GSK Investigational Site, Immokalee

35205

GSK Investigational Site, Birmingham

37760

GSK Investigational Site, Jefferson City

37912

GSK Investigational Site, Nashville

38119

GSK Investigational Site, Memphis

45236

GSK Investigational Site, Cincinnati

46383

GSK Investigational Site, Valparaiso

46544

GSK Investigational Site, Mishawaka

47714

GSK Investigational Site, Evansville

50010

GSK Investigational Site, Ames

55402

GSK Investigational Site, Minneapolis

60640

GSK Investigational Site, Chicago

63141

GSK Investigational Site, St Louis

67042

GSK Investigational Site, El Dorado

68046

GSK Investigational Site, Papillion

68803

GSK Investigational Site, Grand Island

73013

GSK Investigational Site, Edmond

78229

GSK Investigational Site, San Antonio

78237

GSK Investigational Site, San Antonio

78745

GSK Investigational Site, Austin

80012

GSK Investigational Site, Aurora

85281

GSK Investigational Site, Tempe

89030

GSK Investigational Site, North Las Vegas

91303

GSK Investigational Site, Canoga Park

92324

GSK Investigational Site, Colton

94598

GSK Investigational Site, Walnut Creek

95864

GSK Investigational Site, Sacramento

92103-6204

GSK Investigational Site, San Diego

01844

GSK Investigational Site, Methuen

07059

GSK Investigational Site, Warren Township

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05559476 - A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above | Biotech Hunter | Biotech Hunter